Abstract
Objective: The aim of the present study was to design an efficient delivery system with an anticipated swelling and drug release properties for a prolonged drug release as well as to target colon for various hydrophilic drugs.
Method: For this purpose, the pH-responsive hydrogel comprising a combination of Eudragit and acrylic acid was formed. The hydrogels were characterized for spectral (FTIR), thermal (TGA/DSC), structural (XRD), and morphological (SEM) investigations. Oral tolerability was assessed in rabbits for biocompatibility and oral use of the prepared hydrogels.
Results: The results showed that an increased incorporation of Eudragit and cross-linking agent retorted the swelling, drug loading, and drug release properties at both acid (pH 1.2) and basic pH (pH 6.8 and 7.4) , while acrylic acid presented the inverse results. The oral tolerability and toxicity studies depicted that the developed hydrogels were safe up to 3800 mg/kg body weight and caused no hematological or histopathological changes when compared with the control group.
Conclusion: Therefore, the newly developed formulations presented adequate swelling, drug loading, release behavior, and biocompatibility properties and thus can be used as a promising tool for the colonic delivery of various hydrophilic drugs.
Keywords: Eudragit S-100, acrylic acid, crosslinking, colonic delivery, losartan potassium, drug delivery.
Graphical Abstract
[http://dx.doi.org/10.1016/j.msec.2015.07.053] [PMID: 26354282]
[http://dx.doi.org/10.1016/j.carbpol.2011.12.022]
[http://dx.doi.org/10.1007/s10856-010-4134-1] [PMID: 20686825]
[http://dx.doi.org/10.1208/pt0801012] [PMID: 17408212]
[http://dx.doi.org/10.1016/S0378-5173(00)00650-5] [PMID: 11165097]
[http://dx.doi.org/10.1016/j.polymdegradstab.2007.02.011]
[http://dx.doi.org/10.1163/138577211X557521]
[PMID: 20524422]
[http://dx.doi.org/10.1016/j.jopr.2013.04.015]
[http://dx.doi.org/[http://10.1155/2015/187961]
[http://dx.doi.org/10.1002/adv.21747]
[http://dx.doi.org/10.1080/03639040701744079] [PMID: 18473234]
[http://dx.doi.org/10.1016/j.ijbiomac.2018.10.203] [PMID: 30389527]
[http://dx.doi.org/10.1007/s12034-011-0356-1]
[http://dx.doi.org/10.1021/mp500337r] [PMID: 25157890]
[http://dx.doi.org/10.1016/j.ijbiomac.2018.05.057] [PMID: 29758310]
[http://dx.doi.org/10.2174/1567201815666180502165436] [PMID: 29732987]
[http://dx.doi.org/10.1080/22297928.2016.1209427]
[http://dx.doi.org/10.1016/j.carbpol.2017.02.080] [PMID: 28385222]
[http://dx.doi.org/10.1016/j.carbpol.2008.06.013]
[http://dx.doi.org/10.1186/2008-2231-21-44] [PMID: 23721569]
[http://dx.doi.org/10.3109/03639049809089946] [PMID: 9876557]
[http://dx.doi.org/10.1016/j.msec.2017.03.163] [PMID: 28482615]
[http://dx.doi.org/10.1080/15685551.2016.1259834] [PMID: 29491802]
[http://dx.doi.org/10.3329/jsr.v7i1-2.21182]
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.013] [PMID: 25865571]
[http://dx.doi.org/10.1016/j.carbpol.2005.12.014]
[http://dx.doi.org/10.1016/j.eurpolymj.2004.01.039]
[http://dx.doi.org/10.1016/S0009-2509(00)00547-9]
[http://dx.doi.org/10.1016/j.polymer.2003.12.040]
[PMID: 22568051]
[http://dx.doi.org/10.1016/j.carbpol.2007.02.016]
[http://dx.doi.org/10.1016/S1773-2247(09)50085-8]
[http://dx.doi.org/10.1016/j.ijpharm.2012.12.024] [PMID: 23266758]
[PMID: 27008813]
[http://dx.doi.org/10.4314/tjpr.v8i2.44523]
[http://dx.doi.org/10.1016/j.ijpharm.2017.09.034] [PMID: 28947244]
[http://dx.doi.org/10.1002/app.45312]